Clinical trials: Cancer of the Head and Neck
Primary Esophageal Carcinoma
Angiogenic Factor Expression During Fractionated Irradiation
The main question of this study is if and when VEGF (vascular endothelial growth factor) expression in the tumor is upregulated during chemoradiation and if bevacizumab inhibits subsequent vessel growth in the tumor.
- Trial name
- NCT02072720
- Testing
- Bevacizumab
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Head and Neck Neoplasm
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy.
- Trial name
- DEHART (NCT04477759)
- Testing
- 50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Squamous Cell Carcinoma of the Head and Neck
Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN
The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.
- Trial name
- NCT03880396
- Testing
- hypofractionated Rth with platinol
- Where
- Egypt
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Assiut University
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Squamous Cell Cancer of the Head and Neck
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
The standard treatment for head and neck cancer relapses in previously irradiated patients is controversial. Reirradiation has had some success, but many patients still die from their disease.
- Trial name
- NCT00934518
- Testing
- Radiation, Cetuximab
- Where
- United States
- Sponsor
- Milton S. Hershey Medical Center
Squamous Cell Carcinoma Of The Head And Neck
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached…
- Trial name
- NCT01488318
- Testing
- Cetuximab, Dasatinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Julie E. Bauman, MD, MPH
Head and Neck Cancer, Xerostomia Following Radiotherapy
Laser Acupoints Stimulation on Xerostomia Related Chemoradiotherapy for Head and Neck Cancer Patients
The purpose of the study is to evaluate to effect of LASER acupoints stimulations on xerostomia patients during chemoradiation therapy after head and neck cancer.
- Trial name
- NCT07029854
- Testing
- Medical treatment, LASER acupoints therapy, Pseudo-LASER acupoints therapy
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Cairo University
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Squamous Cell Carcinoma of the Oral Cavity
Contribution of Residual Tumour DNA Testing on the Surgical Bed
The aim of this study is to evaluate the interest of residual tumour DNA research in the operating bed after squamous cell carcinoma excision.
- Trial name
- MARGINS (NCT05934929)
- Testing
- Circulating tumor DNA detection
- Where
- 2 sites in France
- Volunteers
- 31 people
- Sponsor
- Centre Henri Becquerel
Head and Neck Cancer
Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia
Patients with locally advanced head and neck cancer treated with chemo-radiotherapy have (during and shortly after this treatment) a high risk of developing pneumonia by aspiration.
- Trial name
- PANTAP (NCT01598402)
- Testing
- amoxicillin/clavulanic acid suspension
- Where
- 6 sites in Netherlands
- Volunteers
- 106 people
- Sponsor
- Radboud University Medical Center
Thyroid Nodules
Elastography Interest in the Management of Thyroid Nodules
Define an ultrasound/elastography benignity criteria in strategy management of a patient population carries one or more thyroid nodules.
- Trial name
- SWETHY (NCT01335828)
- Testing
- Medical ultrasound device (ShearWave system)
- Where
- France
- Volunteers
- 125 people
- Sponsor
- AdministrateurCIC
Solid Tumor, Adult, Head and Neck Cancer
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03543813
- Testing
- CX-2029
- Where
- 25 sites in United States, South Korea and 2 more
- Volunteers
- 133 people
- Sponsor
- CytomX Therapeutics
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Head and Neck Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
- Trial name
- NCT00021424
- Testing
- recombinant fowlpox-TRICOM vaccine
- Where
- United States
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Oral Cavity Cancer
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.
- Trial name
- NCT01116843
- Testing
- PF-00299804
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
China with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year.
- Trial name
- NCT04666090
- Testing
- Carillizumab, Esophagectomy, Samples
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and…
- Trial name
- NCT04868162
- Testing
- MRG003, MRG003+HX008
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Esophagus Cancer
The Efficacy and Safety of Caffeic Acid for Esophageal Cancer
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- CAEC (NCT03070262)
- Testing
- CA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.